Literature DB >> 23670248

Restricted calorie ketogenic diet for the treatment of glioblastoma multiforme.

Joseph Maroon1, Jeffrey Bost, Austin Amos, Giulio Zuccoli.   

Abstract

Glioblastoma multiforme is the most common malignant primary brain tumor in adults and generally considered to be universally fatal. Glioblastoma multiforme accounts for 12% to 15% of all intracranial neoplasms and affects 2 to 3 adults per every 100,000 in the United States annually. In children glioblastoma multiforme accounts for only approximately 7% to 9% of central nervous system tumors. The mean survival rate in adults after diagnosis ranges from 12 to 18 months with standard therapy and 3 to 6 months without therapy. The prognosis in children is better compared to adult tumor onset with a mean survival of approximately 4 years following gross total surgical resection and chemotherapy. There have been few advances in the treatment of glioblastoma multiforme in the past 40 years beyond surgery, radiotherapy, chemotherapy, and corticosteroids. For this reason a restrictive calorie ketogenic diet, similar to that used in children to control drug resistant seizure activity, has been advanced as an alternative adjunctive treatment to help prolonged survival. This article reviews the science of tumor metabolism and discusses the mechanism of calorie restriction, cellular energy metabolism, and how dietary induced ketosis can inhibit cancer cell's energy supply to slow tumor growth.

Entities:  

Keywords:  Warburg Effect; glioblastoma multiforme; glycolysis; ketogenic diet

Mesh:

Substances:

Year:  2013        PMID: 23670248     DOI: 10.1177/0883073813488670

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  12 in total

Review 1.  Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs.

Authors:  C von Neubeck; A Seidlitz; H H Kitzler; B Beuthien-Baumann; M Krause
Journal:  Br J Radiol       Date:  2015-07-10       Impact factor: 3.039

2.  Cystic glioblastoma multiforme masquerading as a cerebral tuberculoma.

Authors:  Mahboob Hasan; Bushra Siddiqui; Shagufta Qadri; Shahbaz Faridi
Journal:  BMJ Case Rep       Date:  2014-10-17

3.  Inhibition of Neuroblastoma Tumor Growth by Ketogenic Diet and/or Calorie Restriction in a CD1-Nu Mouse Model.

Authors:  Raphael Johannes Morscher; Sepideh Aminzadeh-Gohari; René Gunther Feichtinger; Johannes Adalbert Mayr; Roland Lang; Daniel Neureiter; Wolfgang Sperl; Barbara Kofler
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

Review 4.  The Efficacy of Ketogenic Diet and Associated Hypoglycemia as an Adjuvant Therapy for High-Grade Gliomas: A Review of the Literature.

Authors:  Kunal Varshneya; Christine Carico; Alicia Ortega; Chirag G Patil
Journal:  Cureus       Date:  2015-02-27

5.  Ketolytic and glycolytic enzymatic expression profiles in malignant gliomas: implication for ketogenic diet therapy.

Authors:  Howard T Chang; Lawrence Karl Olson; Kenneth A Schwartz
Journal:  Nutr Metab (Lond)       Date:  2013-07-05       Impact factor: 4.169

6.  Roles of caloric restriction, ketogenic diet and intermittent fasting during initiation, progression and metastasis of cancer in animal models: a systematic review and meta-analysis.

Authors:  Mengmeng Lv; Xingya Zhu; Hao Wang; Feng Wang; Wenxian Guan
Journal:  PLoS One       Date:  2014-12-11       Impact factor: 3.240

7.  Treatment of glioma patients with ketogenic diets: report of two cases treated with an IRB-approved energy-restricted ketogenic diet protocol and review of the literature.

Authors:  Kenneth Schwartz; Howard T Chang; Michele Nikolai; Joseph Pernicone; Sherman Rhee; Karl Olson; Peter C Kurniali; Norman G Hord; Mary Noel
Journal:  Cancer Metab       Date:  2015-03-25

Review 8.  Tumor Cells Growth and Survival Time with the Ketogenic Diet in Animal Models: A Systematic Review.

Authors:  Soheila Khodadadi; Nafiseh Sobhani; Somaye Mirshekar; Reza Ghiasvand; Makan Pourmasoumi; Maryam Miraghajani; Somayeh Shahraki Dehsoukhteh
Journal:  Int J Prev Med       Date:  2017-05-25

9.  Combination of metronomic cyclophosphamide and dietary intervention inhibits neuroblastoma growth in a CD1-nu mouse model.

Authors:  Raphael Johannes Morscher; Sepideh Aminzadeh-Gohari; Cornelia Hauser-Kronberger; René Günther Feichtinger; Wolfgang Sperl; Barbara Kofler
Journal:  Oncotarget       Date:  2016-03-29

10.  A novel metabolism-based phenotypic drug discovery platform in zebrafish uncovers HDACs 1 and 3 as a potential combined anti-seizure drug target.

Authors:  Kingsley Ibhazehiebo; Cezar Gavrilovici; Cristiane L de la Hoz; Shun-Chieh Ma; Renata Rehak; Gaurav Kaushik; Paola L Meza Santoscoy; Lucas Scott; Nandan Nath; Do-Young Kim; Jong M Rho; Deborah M Kurrasch
Journal:  Brain       Date:  2018-03-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.